Victoria C. Rosado

Apr 25, 2024 | cell.com | Daniel Maurer |Rebecca L. Ursin |Victoria C. Rosado

Highlights • Natural HA affinity for human bnAb precursors is transduced into vaccine nanoparticles • A humanized mouse is engineered to contain human bnAb precursor frequency • Vaccine protection against group 1 + group 2 IAV is generated by stem bnAb elicitation • The antibodies undergo a single amino acid “switch” to accommodate IAV glycan diversity Summary Broadly neutralizing antibodies (bnAbs) targeting the hemagglutinin (HA) stem of influenza A viruses (IAVs) tend to be effective...